当前位置：
X-MOL 学术
›
Diabetes Obes. Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2020-02-12 , DOI: 10.1111/dom.13997 Juan P Frias 1 , Guillermo Gonzalez-Galvez 2 , Eva Johnsson 3 , Jill Maaske 4 , Marcia A Testa 5 , Donald C Simonson 6, 7 , Nalina Dronamraju 3 , Ricardo Garcia-Sanchez 4 , Anne L Peters 8
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2020-02-12 , DOI: 10.1111/dom.13997 Juan P Frias 1 , Guillermo Gonzalez-Galvez 2 , Eva Johnsson 3 , Jill Maaske 4 , Marcia A Testa 5 , Donald C Simonson 6, 7 , Nalina Dronamraju 3 , Ricardo Garcia-Sanchez 4 , Anne L Peters 8
Affiliation
To evaluate the efficacy and safety of dapagliflozin (DAPA) + saxagliptin (SAXA) compared with glimepiride (GLIM) in patients with type 2 diabetes who were inadequately controlled [glycated haemoglobin (HbA1c) 7.5–10.5% (58–91 mmol/mol)] on metformin monotherapy.
中文翻译：
在稳定剂量的二甲双胍中，达帕格列净+沙格列汀与格列美脲双重联用疗法对2型糖尿病控制不良的患者的疗效和安全性：一项为期52周的随机，主动，对照试验得出的结果。
为了评估达格列净（DAPA）+沙格列汀（SAXA）与格列美脲（GLIM）相比在2型糖尿病患者中的控制效果和安全性[糖化血红蛋白（HbA1c）7.5–10.5％（58–91 mmol / mol）二甲双胍单药治疗。
更新日期：2020-02-12
中文翻译：
在稳定剂量的二甲双胍中，达帕格列净+沙格列汀与格列美脲双重联用疗法对2型糖尿病控制不良的患者的疗效和安全性：一项为期52周的随机，主动，对照试验得出的结果。
为了评估达格列净（DAPA）+沙格列汀（SAXA）与格列美脲（GLIM）相比在2型糖尿病患者中的控制效果和安全性[糖化血红蛋白（HbA1c）7.5–10.5％（58–91 mmol / mol）二甲双胍单药治疗。
京公网安备 11010802027423号